NZ729564A - A2a antagonists as cognition and motor function enhancers - Google Patents
A2a antagonists as cognition and motor function enhancersInfo
- Publication number
- NZ729564A NZ729564A NZ729564A NZ72956411A NZ729564A NZ 729564 A NZ729564 A NZ 729564A NZ 729564 A NZ729564 A NZ 729564A NZ 72956411 A NZ72956411 A NZ 72956411A NZ 729564 A NZ729564 A NZ 729564A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cognition
- motor function
- antagonists
- adenosine
- antagonist
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Methods are described for inducing cognition and motor function enhancement in patients suffering from Parkinson’s disease by administering an effective amount of an Adenosine 2a antagonist such as 4-hydroxy-4-methylpiperidine-1-carboxylic acid-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide (TOZADENANT, SYN115). The Adenosine 2a antagonist can optionally be administered in combination with a dopamine precursor, such as levodopa, or a dopamine receptor agonist.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ746118A NZ746118A (en) | 2010-11-05 | 2011-11-04 | A2a antagonists as cognition and motor function enhancers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2010/055681 WO2012060844A1 (en) | 2010-11-05 | 2010-11-05 | A2a antagonists as cognition and motor function enhancers |
NZ71087611 | 2011-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ729564A true NZ729564A (en) | 2018-09-28 |
Family
ID=66476976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ729564A NZ729564A (en) | 2010-11-05 | 2011-11-04 | A2a antagonists as cognition and motor function enhancers |
Country Status (1)
Country | Link |
---|---|
NZ (1) | NZ729564A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10653699B2 (en) | 2015-06-19 | 2020-05-19 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
-
2011
- 2011-11-04 NZ NZ729564A patent/NZ729564A/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10653699B2 (en) | 2015-06-19 | 2020-05-19 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ746118A (en) | A2a antagonists as cognition and motor function enhancers | |
MY162895A (en) | A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease | |
MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
BR112012020273A2 (en) | PYRAZOLOPYRIDINE COMPOUNDS, PIRAZOLOPYRAZINE, PYRAZOLOPYRIMIDINE, PYRAZOLOTHIOPHENE AND PYRAZOLOTHIAZOLE AS MGLUR4 ALLOSTERIC POINTENTIALIZERS, COMPOSITIONS AND METHODS OF TREATMENT OF NEUROLOGICAL DYSFUNCTION | |
AR098741A1 (en) | DUAL AGONISTS OF THE GLP-1 RECEIVER (PEPTIDE SIMILAR TO GLUCAGON 1) / GLUCAGÓN | |
MX2011008450A (en) | Agonists and antagonists of the s1p5 receptor, and methods of uses thereof. | |
EP4324479A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
EA201270467A1 (en) | POLYCYCLIC CONNECTIONS AS ANTAGONISTS OF LYSOPHOSPHATID ACID RECEPTORS | |
TN2011000160A1 (en) | Combination of an insulin and a glp -1 agonist | |
EA201001253A1 (en) | N, N-DESIGNED AMINOALKYLBIPHENYLES AS ANTAGONISTS OF PROSTAGLANDIN RECEPTORS D | |
IN2012DN02735A (en) | ||
IN2012DN00754A (en) | ||
TN2011000040A1 (en) | Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists | |
MX2010004281A (en) | Compositions and methods for treatment of diabetic retinopathy. | |
CR11849A (en) | MIXED AGONISTS, BASED ON GIP FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY | |
EA201290266A1 (en) | ANTAGONIST COMBINATIONS OF MUSCARIN RECEPTORS AND BETA-2 ADRENORECEPTOR AGONIST | |
HU0800434D0 (en) | Template to determine the places of the injections, especially for regular medicament injection and/or blood testing | |
EA201270264A1 (en) | Treatment of metastases in the brain | |
MX348933B (en) | Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound. | |
CY1119560T1 (en) | METHODS TO REDUCE ADOPTIVE DISORDER OR MENTAL HEALTH | |
EA201001162A1 (en) | METHODS OF TREATMENT OF DISORDERS WITH REDUCTION OF BONE MASS USING AN ANTAGONIST GM-CSF | |
NZ598247A (en) | Compositions and methods for treating parkinson’s disease | |
NZ729564A (en) | A2a antagonists as cognition and motor function enhancers | |
MX2014014813A (en) | Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders. | |
MX2019009243A (en) | Methods for treating or preventing asthma by administering an il-4r antagonist. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 04 NOV 2021 BY AJ PARK Effective date: 20190426 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 NOV 2022 BY CPA GLOBAL Effective date: 20210924 |
|
LAPS | Patent lapsed |